为应对新型冠状病毒肺炎（COVID-19）突发公共卫生事件，2020年3月，FDA发布“FD&C法案506C规定的永久停产和生产中断报告指导原则”。该指导原则为申请人和生产企业及时和详尽地报告药品和生物制品生产变化提出建议，以便FDA采取及时有效的措施应对可能的短缺药品，保障美国药品供应链稳定。该指导原则对完善我国药品生产中断报告制度具有参考价值。

In light of the Coronavirus Disease 2019 (COVID-19) public health emergency in America, FDA issued Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing Under Section 506C of the FD&C Act Guidance for Industry in March 2020. This guidance aimed to assist applicants and manufacturers in providing FDA timely, informative notifications about changes in the production of certain drugs and biological products, in turn, help the Agency in its efforts to prevent or mitigate shortages of such products, so as to ensure the stability of the medical product supply chain in America. This guidance was still useful for perfecting interruption in manufacturing reporting system of China.